Picture of Fulcrum Therapeutics logo

FULC Fulcrum Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Fulcrum Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

* Fulcrum Therapeutics Inc  FULC.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -50 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 43 cents per
share. Wall Street expected results to range from -50 cents
to -38 cents per share.
    * Revenue rose 27.2% to $871.00 thousand from a year ago;
analysts
expected $461.17 thousand. 
    * Fulcrum Therapeutics Inc's reported EPS for the quarter
was a
loss of 40 cents​.
    * The company reported a quarterly loss of $24.76 million.
    * Fulcrum Therapeutics Inc shares had risen by 44.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $11.00 
This summary was machine generated from LSEG data February 27 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.43          -0.40          Beat
 Sep. 30 2023      -0.43          -0.39          Beat
 Jun. 30 2023      -0.44          -0.38          Beat
 Mar. 31 2023      -0.46          -0.41          Beat

Recent news on Fulcrum Therapeutics

See all news